Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Enough Being Done About Cybersecurity In The EU? Contradictory Views Raise Regulatory Questions

Executive Summary

A recent report from the UK Royal Academy of Engineering suggests that more efforts are needed to ensure cybersecurity protections for medical devices. But a key European industry trade association says that cybersecurity is adequately addressed from a regulatory standpoint in the EU.

You may also be interested in...



EU MDR and IVDR Cybersecurity Measures Not Enough To Prevent Attacks, Warns ENISA

An expert from the European Union Agency for Cybersecurity (ENISA) has told Medtech Insight that although the new EU Medical Device and IVD Regulations will push developers to make more secure products, regulation is not enough to prevent cyberattacks on devices and digital health systems.

Medtech Security Organization Adopts Widely Used Automation Cybersecurity Standard

The medtech cybersecurity group MDISS says it will adopt the ISA/IEC 62443 cybersecurity standard that has been widely used in an array of industries for the medical device industry. This comes following news from the European medtech group COCIR that it was also considering adopting the standard.

China's Latest Cybersecurity Proposal Could Heighten Scrutiny On Device, Drug Industries

Medtech and biopharma are among key information infrastructure industries likely subject to additional security and reporting obligations under draft legislation, adding costs and even potentially causing business disruptions, legal experts say.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel